Loading...
•
Dec 31, 2024
BioLife Q4 2024 Earnings Report
BioLife Solutions reported Q4 2024 results with strong revenue growth, improved margins, and reduced losses.
Key Takeaways
BioLife Solutions posted $22.7 million in revenue for Q4 2024, a 31% increase YoY. The company improved its gross margin to 60% GAAP (63% non-GAAP). Net loss narrowed to $2.0 million, while non-GAAP adjusted EBITDA was $4.0 million. The Cell Processing platform led growth with a 37% YoY revenue increase.
Total revenue grew 31% YoY to $22.7 million.
Cell Processing platform revenue increased 37% YoY to $20.3 million.
Gross margin improved to 60% GAAP, 63% non-GAAP.
Net loss reduced to $2.0 million from $7.2 million YoY.
Revenue by Segment
Forward Guidance
BioLife Solutions expects total revenue growth of 16-20% in 2025, driven by an 18-21% increase in the Cell Processing platform. The company anticipates maintaining strong gross margins and further reducing net losses.
Positive Outlook
- Projected revenue growth of 16-20% in 2025.
- Cell Processing platform expected to grow 18-21%.
- Gross margin to remain in the low 60% range.
- Adjusted EBITDA margin expected to expand.
- Increased cross-selling opportunities in biopreservation.
Challenges Ahead
- Continued net losses expected, though reduced.
- Operating loss still a concern despite improvement.
- Evo & Thaw platform growth expected to be modest (3-15%).
- Macroeconomic risks could impact revenue projections.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...